Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Related Stories
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 3 months
Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 4 months
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio / 3 months
Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 2 months
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 3 months
Eli Lilly buys Centessa for $6.3B to enter sleep disorder market / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Venture Capital, Alzheimer's disease, Animal Health, Medicaid and look for the RSS link.
StackHealth Time Machine